H-1 NMR and molecular modeling study on the inclusion complex beta-cyclodextrin indomethacin

被引:89
作者
Fronza, G [1 ]
Mele, A [1 ]
Redenti, E [1 ]
Ventura, P [1 ]
机构
[1] CHIM FARMACEUT SPA,CHEM & BIOPHARMACEUT DEPT,I-43100 PARMA,ITALY
关键词
D O I
10.1021/jo951410m
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The solution structure of the inclusion complex between beta-cyclodextrin (2) and the nonsteroidal anti-inflammatory agent indomethacin sodium salt(1) [1-(p-chlorobenzoyl)-5-methoxy-2-methylindoleacetic acid sodium salt] is investigated in D2O solution via H-1 NMR spectroscopy. The guest molecule 1 exists in solution as a mixture off and Z isomers in fast exchange on the NMR time scale, as shown by NOE experiments. Low-temperature H-1 NMR spectra on indomethacin methyl ester (3) (soluble in CH2Cl2-d(2)) showed that the Z isomer is the most thermodynamically stable, Geometrical features of the host-guest inclusion complex between 2 and 1 are inferred from intermolecular dipolar contacts obtained by 1D NOE difference spectra and 2D ROESY experiments. A more detailed picture of the solution structure of the complex is obtained by combining NMR structural information and molecular dynamics and energy calculations on the inclusion complexes. Computations took into account the existence of two diastereomeric forms of the guest (E and Z), the two possible sites of interaction of the guest molecule with the cavity (i.e. the p-chlorobenzoyl ring and the indole ring system), and the different topologies for the entry of the guest into the host's cavity. The main finding that can be obtained from both experimental and theoretical data is that the complexation selectively stabilizes the E isomer with respect to Z. The inclusion complex is characterized by the interaction of the p-chlorobenzoyl moiety of 1E with the lipophilic cavity of the host 2, the entry being through the larger rim of the truncated cone of 2.
引用
收藏
页码:909 / 914
页数:6
相关论文
共 23 条
[1]   MOLECULAR MODELING OF BETA-CYCLODEXTRIN COMPLEXES WITH NOOTROPIC DRUGS [J].
AMATO, ME ;
DJEDAINI, F ;
PAPPALARDO, GC ;
PERLY, B ;
SCARLATA, G .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (12) :1157-1161
[2]  
DAUGEROSGUTHORP.P, 1988, PROTEIN-STRUCT FUNCT, V4, P31
[3]  
Demarco P.V., 1970, CHEM COMMUN, P2, DOI [DOI 10.1039/C29700000002, 10.1039/C29700000002]
[4]   THE DEVELOPMENT AND USE OF QUANTUM-MECHANICAL MOLECULAR-MODELS .76. AM1 - A NEW GENERAL-PURPOSE QUANTUM-MECHANICAL MOLECULAR-MODEL [J].
DEWAR, MJS ;
ZOEBISCH, EG ;
HEALY, EF ;
STEWART, JJP .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1985, 107 (13) :3902-3909
[5]  
DJEDAINI F, 1990, J PHARM SCI, V79, P1184
[6]   CONFORMATIONAL-ANALYSIS OF MAJOR METABOLITES OF MACROLIDE ANTIBIOTICS ROXITHROMYCIN AND ERYTHROMYCIN-A WITH DIFFERENT BIOLOGICAL PROPERTIES BY NMR-SPECTROSCOPY AND MOLECULAR-DYNAMICS [J].
GHARBIBENAROUS, J ;
LADAM, P ;
DELAFORGE, M ;
GIRAULT, JP .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1993, (11) :2303-2315
[7]   MODEL FOR PROSTAGLANDIN SYNTHETASE CYCLO-OXYGENATION SITE AND ITS INHIBITION BY ANTIINFLAMMATORY ARYLACETIC ACIDS [J].
GUND, P ;
SHEN, TY .
JOURNAL OF MEDICINAL CHEMISTRY, 1977, 20 (09) :1146-1152
[8]   INCLUSION COMPLEXATIONS OF INDOMETHACIN AND ITS RELATED-COMPOUNDS WITH CYCLODEXTRINS IN AQUEOUS-SOLUTION [J].
HOSHINO, T ;
TAGAWA, Y ;
HIRAYAMA, F ;
OTAGIRI, M ;
UEKAMA, K .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1982, 102 (12) :1184-1190
[9]  
Inoue Y., 1993, Annual Reports on NMR Spectroscopy, VVolume 27, P59, DOI DOI 10.1016/S0066-4103(08)60265-3
[10]  
JACKMAN LM, 1969, APPLICATIONS NUCLEAR, P207